A Study of PCSK9 Inhibitor AK102 in Healthy Subjects
Status:
Completed
Trial end date:
2019-06-30
Target enrollment:
Participant gender:
Summary
This is a first-in-human,randomized, double-blind, placebo-controlled, single dose
escalation, phase 1 study to evaluate the safety, tolerability, PK/PD and immunogenicity of
AK102 administered subcutaneously in healthy subjects. Subjects will be randomized into 4
planned single dose escalation cohorts or placebo cohort.
Phase:
Phase 1
Details
Lead Sponsor:
Akeso
Collaborators:
AD Pharmaceuticals Co., Ltd. AD Pharmaceuticals Co., Ltd. (Guangzhou)